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Abstract: First-line therapies in the treatment of patients with mild-to-moderate ulcerative 
colitis are sulfasalazine or one of the mesalamine derivatives. Mesalamine is popular given 
its safety proﬁ  le and reasonable efﬁ  cacy in many patients. However, compliance is poor with 
regimens demanding large number of pills dosed multiple times a day and non-compliance 
has been correlated with disease relapse. Mesalamine requires direct contact with the inﬂ  amed 
colonic mucosa. To avoid proximal absorption, a variety of delivery systems has been utilized 
to time the release of active mesalamine to the areas affected by colitis. The most common 
mesalamine release mechanisms include azo-bond prodrug carriers, pH-dependent dissolution, 
and moisture-sensitive product dispersion. Novel technology has resulted in the development 
and FDA-approval of a multi-matrix release (MMX) mesalamine. Pharmacodynamic studies 
suggest a reliable drug delivery system with homogenous release throughout the entire colon. By 
incorporating the largest amount of mesalamine (1.2 g) per pill, this new product dramatically 
decreases the number of pills needed to attain a therapeutic daily dosage, and is the ﬁ  rst agent 
approved at once-daily dosing. These factors are expected to increase patient compliance with 
prescribed mesalamine dosing, and in turn decrease relapse rates of active ulcerative colitis.
Keywords: mesalamine, sulfasalazine, balsalazide, olsalazine, ulcerative colitis, inﬂ  ammatory 
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Introduction
Ulcerative colitis (UC) is a chronic disease characterized by periods of active disease 
and remission that result in inﬂ  ammation of the colonic mucosa. Patients often expe-
rience symptoms of abdominal pain, diarrhea, rectal bleeding, fatigue, weight loss, 
and loss of appetite. UC has various extraintestinal manifestations such as arthritis, 
inﬂ  ammation of the eye, liver and biliary disease, rashes, anemia, and osteoporosis, 
which can all worsen patients’ quality of life (QoL) during active episodes.
The pathologic mechanism of UC is unknown. However it is hypothesized that 
an overly active immune system may cause colonic inﬂ  ammation in response to a 
variety of triggers including dietary substances, unknown infectious agents, and/or 
common colonic bacteria (Wen and Fiocchi 2004; Kovvali et al 2005). The genetic 
predisposition to developing ulcerative colitis is also a complex matter, with multiple 
genes likely responsible, varying in different populations (Yang et al 1993; Mansﬁ  eld 
et al 1994).
Although UC can manifest symptoms at any age, patients are usually diagnosed 
between the ages of 15 to 30 years. In the Western world, the prevalence of UC has 
been shown to be over 200 cases per 100,000 people, with an incidence rate of 7 new 
cases in 100,000 per year (Ghosh et al 2000; Loftus et al 2000).
Ulcerative colitis (UC) almost always involves the rectum and a continuous por-
tion of the colon. Inﬂ  ammation is most often limited to the left side of the colon in the 
majority of UC patients. Approximately 33%–55% of patients fall into the category Therapeutics and Clinical Risk Management 2007:3(5) 920
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of proctitis, which is disease limited to the rectum or the 
rectosigmoid, while about 30% exhibit colitis extending 
to the splenic ﬂ  exure (∼60 cm from the anal verge), and 
15%–30% with extensive colitis, extending proximally 
beyond the splenic ﬂ  exure. Approximately 15% of patients 
have extensive colitis, which is disease extending beyond 
the splenic ﬂ  exure (Farmer et al 1993; Langholz et al 1996; 
Ghosh et al 2000).
Most patients will experience at least one relapse during 
the course of their disease. A population-based study showed 
that while 50% of UC patients are asymptomatic at any given 
time, about 97% experience at least one relapse of symptoms 
in a 10-year time-span (Hendriksen et al 1985). The progres-
sion and manifestation of UC varies greatly between patients 
on a yearly basis and symptomatic relapses can range from 
insigniﬁ  cant to incapacitating. Current disease trends show 
that patients are less likely to suffer relapses if they have less 
active disease and longer remission periods. Also patients 
who experience frequent relapses are more likely to have 
shorter remission periods (Riley et al 1988a). Therefore, 
the goals of current therapy for UC are to reduce symptoms 
during periods of active disease and prolong the duration of 
symptom-free remission periods.
Rationale for use of mesalamine in UC
Aminosalicylates are at present the treatment of choice for ﬁ  rst 
line therapy of mild-to-moderate ulcerative colitis, with demon-
strated efﬁ  cacy and safety in patients with UC (Sutherland et al 
2002). The exact mechanisms of aminosalicylates’ actions are 
unknown. Studies suggest that there is a multifactorial basis for 
their anti-inﬂ  ammatory and immunosuppressive efﬁ  cacy. Due 
to its negative effect on the cyclooxygenase and lypoxygenase 
pathways, mesalamine (5-aminosalicylic acid) prevents the for-
mation of inﬂ  ammatory agents like prostaglandins and leukot-
rienes (Ligumsky et al 1981; Hawkey et al 1985). Studies have 
also shown that because of their negative effects on free-radical 
scavenging in the intestinal mucosa, mesalamine’s anti-oxidant 
properties may help mitigate tissue injury (Ahnfelt-Ronne et al 
1990). Mesalamine is also suspected to have immunosuppres-
sive activity via inhibiting T-cell activation and proliferation 
in addition to down-regulating cytokine activity (Burress et al 
1997; Santucci et al 2005).
Although the exact mechanism is uncertain, mesalamine is 
thought to have topical anti-inﬂ  ammatory activity in the colon. 
Therefore, the clinical goal is to deliver as much active drug 
to the affected portions of the colonic mucosa while minimiz-
ing systemic absorption in efforts to reduce adverse effects. 
The efﬁ  cacy of mesalamine-based compounds is associated 
with the local concentration of the drug and by the amount 
of active substance that reaches the diseased site (Ardizzone 
et al 1999; Pokrotnieks et al 2000).
The usefulness of sulfasalazine, along with oral mesa-
lamine compounds, for inducing remission in patients with 
active ulcerative colitis has been shown in various studies.   
(Sutherland et al 2000; Sninsky et al 1991; Singleton et al 1993; 
Hanauer et al 1993; Green et al 1998) A recent meta-analysis 
encompassing studies from 1981–2005 demonstrated that 
mesalamine was superior to placebo in regards to measured 
outcomes, which were induction of clinical remission, clinical 
improvement, endoscopic remission, and endoscopic improve-
ment (Sutherland and Macdonald 2006a).
There have also been various studies looking at the efﬁ  -
cacy of mesalamine compounds in maintaining remission 
in UC patients (Miner et al 1995; Modigliani et al 1996; 
The Mesalamine Study Group 1996; Sutherland et al 1997; 
Green et al 1998; Hanauer et al 2000). A recent meta-analysis 
review looked at a large number of similar studies and con-
cluded that mesalamine compounds were superior to placebo 
as a maintenance therapy (Sutherland and Macdonald 2006b). 
The statistical analyses demonstrated that the Peto odds ratio 
for the failure to maintain clinical or endoscopic remission 
(withdrawals and relapses) for mesalamine versus placebo 
was 0.47 (95% CI, 0.36–0.62) with a number-needed-to-treat 
(NNT) of 6.
These data have direct clinical application as several 
studies have shown that the health-related quality of life 
(HRQoL) of patients with UC is related to the severity of 
their symptoms, and that patients experiencing a disease ﬂ  are 
reported signiﬁ  cantly poorer overall HRQoL than those in 
symptomatic remission. Among 160 UC patients with active 
disease, all aspects of HRQoL, as measured by the Inﬂ  amma-
tory Bowel Disease Questionnaire (IBDQ), were signiﬁ  cantly 
lower than for those in symptomatic remission (Casellas et al 
2001). A further, large-scale, multi-center study involving 
528 patients with UC found that patients with active disease 
of any severity experienced impairment in their HRQoL 
across all domains of the IBDQ and patients with moderate 
to severe disease reported the greatest impairment across all 
domains (Casellas et al 2005). Therefore the induction and 
maintenance of remission may be the primary means for 
improving UC patients’ lives on a day-to-day basis.
Review of existing formulations 
of mesalamine
Mesalamine is available in a number of oral and rectal (topi-
cal) formulations including tablets, micropellets (granules), Therapeutics and Clinical Risk Management 2007:3(5) 921
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suppositories, and enemas. Several oral formulations have 
been developed, most of which have been designed with 
various mechanisms to postpone the release of the active 
mesalamine compound until reaching the terminal ileum/
colon in order to prevent proximal absorption in the small 
intestines.
Azo-bonded prodrugs
One group of mesalamine formulations, the azo-bonded 
prodrugs, comprise a mesalamine molecule bound by 
an azo-bond to either a transporter molecule or another 
mesalamine molecule. The azo-bond is cleaved by colonic 
bacteria containing azoreductase enzyme, freeing up the 
active mesalamine. This system helps to maximize delivery 
of mesalamine to the colon by resisting proximal intestinal 
absorption and gastric breakdown.
Sulfasalazine
Sulfasalazine (Azulﬁ  dine®; Pharmacia and Upjohn; Pﬁ  zer; 
New York, NY, USA) was the ﬁ  rst oral formulation of 
mesalamine shown to be effective in the therapy of UC. It 
consists of a sulfapyridine molecule bonded to a mesalamine 
molecule. Sulfasalazine has been show to be effective therapy 
for UC in various studies, which demonstrate that a dose 
of 2–6 g/day can induce remission in about 50%–80% of 
patients (Baron et al 1962; Dick et al 1964). A meta-analysis 
of all oral mesalamine formulations concluded that sulfasala-
zine was associated with a slightly but signiﬁ  cantly higher 
rate of maintenance of UC remission compared with other 
mesalamine formulations at 6 months, but that maintenance 
with sulfasalazine was similar to other mesalamine-agents 
at 12 months (Sutherland and Macdonald 2006b). Because 
of its cost-effectiveness and efﬁ  cacy, sulfasalazine had been 
the mainstay of treatment for UC for almost 40 years. With 
the advent of the non-sulfa-containing mesalamine agents, 
its use has become limited due to a number of demonstrated 
dose-dependent adverse events (including headache, nausea, 
dyspepsia, and allergy) related to the sulfur in the sulfapyri-
dine moiety (Nielsen 1982; Myers et al 1987).
Other azo-bonded drugs have been developed using 
various carrier-molecules other than sulfapyridine in order 
to avoid related side-effects.
Olsalazine sodium
Olsalazine sodium (Dipentum®; UCB Inc., Smyrna, GA, USA) 
consists of two mesalamine molecules linked together by an 
azo-bond. A randomized controlled study with 198 patients 
showed that olsalazine was effective in maintaining remission 
in UC patients after 12 months in a dose-dependent manner 
(Travis et al 1994). Results from the trial demonstrated that 
at 12 months maintenance of remission was achieved in 60% 
of patients receiving 0.5 g/day, 70% of patients receiving 
1.0 g/day, and 78% of patients receiving 2.0 g/day. Due to 
treatment-related side-effects (primarily diarrhea), 12% of 
patients discontinued their treatment. Another study also 
demonstrated that diarrhea is a signiﬁ  cant treatment-related 
side-effect of olsalazine, affecting 16% of patients in the 
olsalazine-arm of the trial (Wright et al 1993; Kruis et al 1995). 
In another study of maintenance of remission in UC, treatment 
failure rates were lower with olsalazine (1.0 g/day) than with 
pH-release mesalamine (1.2 g/day) (24% vs 46%; p = 0.025) 
(Courtney et al 1992).
Balsalazide disodium
Balsalazide disodium (Colazal®; Salix Pharmaceuticals Inc., 
Morrisville, NC, USA) is an azo-bonded drug containing a 
mesalamine molecule bonded to 4-aminobenzoyl-β-alanine 
(4-ABA). Balsalazide has been shown to maintain remission 
of UC in a dose-dependent manner, while minimizing many 
of the treatment-limiting side-effects associated with sul-
fasalazine and olsalazine. One randomized controlled study 
showed the balsalazide maintained remission after 12 months 
in 64% of patients taking 4 g/day and 45% of patients taking 
2 g/day (p < 0.01) (Giaffer et al 1992). Both doses of the drug 
were well-tolerated with about 9% and 12% of patients on the 
2 g/day and 4 g/day dosages withdrawing due to gastrointes-
tinal intolerance. Balsalazide has also been shown to stabilize 
the ﬂ  uctuations in symptom severity by maintaining symptom 
control over the long term in patients with stable remission 
and those with newly attained remission (Green et al 2004). 
One study showed superior clinical remission rates at 1, 2, 
and 3 months with balsalazide 6.75 g/day than with equimolar 
doses of pH-release mesalamine 2.4 g/day (3-month rates: 
62% vs 37%, p = 0.02) (Green et al 1998).
Delayed-release mesalamine
Mesalamine has also been compounded into formulations that 
control the release of the active agent by a variety of mecha-
nisms. One example is pH-release mesalamine (Asacol®; 
Procter & Gamble Pharmaceuticals, Cincinnati, OH, USA), 
which utilizes a gastro-resistant resin ﬁ  lm (eg, Eudragrit-S®) 
that dissolves at a pH of 7 or greater, releasing the active mesa-
lamine. pH-release mesalamine exhibits similar remission rates 
after 48 weeks of treatment compared with sulfasalazine (62% 
vs 61%, p > 0.90) (Riley et al 1988b). However, pH-release 
mesalamine had lower 12-month remission maintenance rates Therapeutics and Clinical Risk Management 2007:3(5) 922
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than olsalazine in a separate study (Courtney et al 1992). While 
data extrapolated from previous clinical trials have suggested 
superior clinical response rates with higher doses of pH-release 
mesalamine, the recent large ASCEND-1 trial found no clear 
dose-related beneﬁ  t between daily doses of 2.4 g vs 4.8 g in the 
treatment of mild-to-moderate UC, although the ASCEND-2 
trial showed a beneﬁ  t in response, but not remission, with the 
4.8 g dose in patients with moderately severe disease (Hanauer 
et al 2005). The most common side-effects associated with 
pH-dependent release mesalamine in a 6-month study were 
headache, ﬂ  u symptoms, diarrhea, rhinitis, and abdominal 
pain (The Mesalamine Study Group 1996).
Moisture-release mesalamine
Moisture-release mesalamine (Pentasa®; Shire US Inc., 
Wayne, PA, USA) consists of microspheres containing mesa-
lamine enclosed within an ethylcellulose semi-permeable 
membrane, which allows time- and moisture-sensitive release 
of the active drug. The mesalamine is released throughout 
the small and large intestines from the duodenum to the rec-
tum, which also makes it a useful treatment for small bowel 
Crohn’s disease. A randomized controlled UC trial showed 
that moisture-release mesalamine maintained remission in 
64% of patients after 12 months when receiving 4 g/day vs 
38% of patients receiving placebo (p = 0.0004) (Miner et al 
1995). The mesalamine was well tolerated; abdominal pain, 
nausea, and hepatitis were the most common treatment-
related adverse events leading to treatment withdrawal.
All of the sulfur-free mesalamine formulations have 
acceptable and similar safety proﬁ  les. Moreover, a recent 
meta-analysis found no signiﬁ  cant difference in systemic 
absorption between various oral mesalamine compounds or 
pro-drug treatments (Sandborn and Hanauer 2003). However, 
a previous study showed that mucosal biopsies taken 1-week 
after cessation of treatment with various oral formulations 
produced an almost 1000-fold variation in mesalamine con-
centration in similar locations throughout patients’ distal 
gastrointestinal tracts, depending upon the agent (De Vos et al 
1992). More recently it has been demonstrated that mesala-
mine concentration is inversely associated with endoscopic 
and histological activity scores in UC (Frieri et al 2000). 
Thus it is possible that the variance in mucosal concentra-
tions of mesalamine between different oral formulations may 
account, in part, for their different efﬁ  cacies.
Mesalamine enemas and suppositories
Mesalamine enemas and suppositories are extremely effec-
tive in the treatment of left-sided ulcerative colitis, ulcerative 
proctosigmoiditis, and ulcerative proctitis (Cohen et al 
2000). Since these agents do not need to protect the mesa-
lamine from digestion, there is no need for a pro-drug or 
controlled-release. These formulations deliver therapeutic 
concentrations of mesalamine to the distal regions of the 
colon, which are sometimes not adequately dosed using 
current oral formulation (Frieri et al 1999). Rectal formula-
tions require patients to retain the formulation for as long as 
possible, which may be difﬁ  cult during times when they are 
suffering from diarrhea. However, such delivery methods 
are associated with leakage as well as problems with reten-
tion, burning sensation and bloating (Gionchetti et al 1999; 
Lim et al 2004). Combination therapies with oral and topical 
mesalamine are superior to oral therapy alone in the treatment 
of active left-sided colitis, and maintenance of remission 
(d’Albasio et al 1997; Safdi et al 1997)
Rationale for once-daily formulations
UC is a chronic, relapsing disease that often requires medica-
tions to maintain a successfully induced response or remis-
sion. Most UC patients will experience at least one relapse 
after their initial diagnosis (Hendriksen et al 1985) and the 
severity of symptoms can intimately affect their HRQoL 
(Casellas et al 2001, 2005) The efﬁ  cacy of a successful 
maintenance regimen depends in part upon patient compli-
ance with the treatment.
Various studies have shown the correlation between com-
pliance and maintenance of remission. In one observational 
study of 94 patients with quiescent UC, only 40% were adher-
ent (deﬁ  ned as reﬁ  lling less than 80% of prescribed dose) with 
their prescribed mesalamine dose (Kane et al 2001). Logistic 
regression identiﬁ  ed male gender and a taking more than 4 
prescription medications as predictors for non-adherence. A 
second study of 99 consecutive UC patients in remission on 
mesalamine therapy revealed that 89% of patients who were 
compliant with their mesalamine remained symptom-free at 
12 months versus 39% of patients who were non-compliant 
(p < 0.001) (Kane et al 2003). Patients who were not adherent 
with their prescribed mesalamine had a greater than a 5-fold 
greater risk of recurrence than adherent patients (p < 0.001). 
Another study aimed at determining compliance of 
patients on sulfasalazine maintenance therapy measured the 
serum sulfapyridine levels in patients during hospitalization 
and at 6 month follow-up (van Hees and van Tongeren 1982). 
Despite instructions to maintain the same dosages as outpa-
tients, serum sulfapyridine levels were substantially lower in 
41% of the patients at the 6-month follow up visit, suggesting 
non-compliance. Furthermore, 21 out of 175 patients had no Therapeutics and Clinical Risk Management 2007:3(5) 923
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detectable level of sulfapyridine in their serum after repeat 
follow-ups up to 4 years, although many still claimed to be 
taking their medication.
The reasons for non-compliance with mesalamine therapy 
are complex and various independent risk factors have been 
identiﬁ  ed, including male gender, single status, full-time 
employment, and 3-times daily dosing (Kane et al 2001; Shale 
and Riley 2003). Also, in patients who are in periods of disease 
remission, the lack of symptomatic reminders may affect their 
ability or interest in complying with complex dosing sched-
ules. The inconvenience of frequent multiple-times-a-day 
dosing, together with the number of tablets/capsules required 
per day, have been identiﬁ  ed as key factors in reducing patient 
compliance with therapy in UC (Kane et al 2003a; Shale and 
Riley 2003). A recent cross-sectional assessed patient com-
pliance with mesalamine maintenance-dosage therapy via 
urine mesalamine levels and direct inquiry (consisting of a 
structured interview and standardized questionnaires) (Shale 
and Riley 2003). Results of the study showed that 43% of 
patients took less than 80% of their prescribed medication and 
12% of patients had no detectable mesalamine in their urine 
at all. When the group patients with disease quiescence were 
questioned about their non-compliance, 70% claimed that they 
had “just forgot”, 30% complained that there were “too many 
pills” to take, and 20% were unconvinced that they needed the 
amount of medicine prescribed (Kane et al 2003a; Shale and 
Riley 2003). These studies imply that many of the existing oral 
formulations of mesalamine require multiple doses per day 
with numerous tablets, and from the information above these 
complicated dosing schedules may conﬂ  ict with the activities 
of daily living of patients and lead to non-compliance.
In an attempt to determine whether once-daily dos-
ing would improve patient outcomes, a small pilot study 
consisting of 22 subjects compared once-daily pH-release 
mesalamine therapy with the conventional 2 or 3 times daily 
dosing in maintaining symptomatic UC remission (Kane et al 
2003b). After 3 months, 100% (12 of 12) of the once-daily 
dosed patients were compliant with their medication regi-
men as opposed to 70% (7 of 10) on the conventional dosing 
regimen (p = 0.04). However by the 6-month follow-up, 1 
patient in each group had experienced symptomatic relapse 
and the compliance rates between groups were comparable. 
Sample size limitations prevented a true assessment of the 
impact of one-daily dosing upon efﬁ  cacy.
Another potential beneﬁ  t of compliance with mesalamine 
therapy has been elucidated by a number of epidemiologic 
studies that have suggested that the regular use of mesalamine 
is associated with about a 2-fold reduction in the probability 
of developing colorectal cancer in UC patients. A meta-
analysis of 116 studies concluded that the risk of patients 
with UC for developing colorectal cancer is 2%, 8%, and 
18% at 10, 20, and 30 years (Eaden et al 2001). Given this 
information, improving patient compliance with mesalamine 
therapy is an important means to improving QoL and long-
term health outcomes in people suffering from UC.
The limitations of current oral mesalamine formulations 
have forced the research and development of new agents 
and regimens that are favorable in ensuring compliance, 
while still maintaining adequate delivery of the drug to the 
affected regions of the colon. Recent developments include 
high-dose tablet formulations to limit the number of pills 
required, once-daily regimens of existing formulations to 
limit the intrusiveness of therapy on daily activities, and novel 
formulations offering more convenient dosing in addition to 
improved drug delivery to the whole colon (Cohen 2006).
Overview of pharmacology of MMX
A novel formulation of oral mesalamine, MMX (SPD476, 
Shire Pharmaceuticals Inc., Wayne PA, USA), is a high 
strength (1.2 g mesalamine/tablet) medication that utilizes a 
Multi-Matrix System™ (MMX) to deliver active aminosalicy-
lates throughout the colon, thus making it a potentially very 
useful treatment in UC.
MMX mesalamine uses a patented polymeric matrix 
model designed with a lipophilic matrix embedded within 
a hydrophilic matrix (Prantera et al 2005). The drug’s core 
holds a lipophilic matrix consisting of mesalamine micropar-
ticles dispersed throughout a hydrophilic matrix, which is 
then surrounded by a pH-dependent (pH 7.0) gastro-resistant 
ﬁ  lm. This design allows the tablet to resist breakdown until 
the terminal ileum where intra-luminal pH levels reach a 
sufﬁ  ciently high level. As the outer coating dissolves, the 
hydrophilic matrix draws in intestinal ﬂ  uid, thus making the 
tablet swell and form a gel-like mass (D’Haens et al 2006). 
This viscous mass tempers the diffusion and breakdown of 
the tablet, thus allowing dissemination of the mesalamine 
molecules in a slow linear kinetics proﬁ  le throughout the 
colon. In addition, studies indicate that the hydrophilic matrix 
may also adhere to the colonic mucosa. This form of delivery 
allows for a more homogenous release of the active drug at 
the ascending, transverse, and descending colon, along with 
the sigmoid and rectum (Prantera et al 2005).
Results of clinical studies
One of the ﬁ  rst trials published to investigate the clini-
cal efﬁ  cacy of MMX mesalamine was the Prantera study Therapeutics and Clinical Risk Management 2007:3(5) 924
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(Prantera et al 2005). The goal of this randomized, double-
blind, double-dummy trial was to judge the therapeutic 
response to MMX in UC patients with left-sided disease 
and assess how this novel formulation would compare with 
topical mesalamine therapy. Seventy-nine patients were ran-
domized to receive either oral MMX mesalamine 3.6 g/day 
(1.2 g tablets dosed 3 times/day) with a bedtime placebo 
enema or similarly dosed oral placebo tablets with a bed-
time mesalamine 4 g/100 mL enema for 8 weeks. Both sets 
of tablets and enemas were visually identical. The primary 
endpoint was the rates of induction of remission at 8 weeks 
between the two groups. Clinical remission was deﬁ  ned 
as a Rachmilewitz (Rachmilewitz 1989) clinical activity 
index (CAI) 4 at 8 weeks. Secondary endpoints were: 
1) duration of symptoms until improvement as measured 
per patient journals and 2) endoscopic/histological improve-
ment, deﬁ  ned by the endoscopic index (EI) developed by 
Rachmilewitz and the score from Floren and colleagues 
(Floren et al 1987). At 8 weeks, clinical remission rates were 
60% for the MMX arm vs 50% in the mesalamine enema 
arm; endoscopic and histological remission rates were 45% 
and 15% vs 37% and 8%, respectively. Compliance rates 
for the MMX group were 97% overall (97% for patients 
in remission and 93% for patients with active symptoms), 
compared with rates of 88% and 66% in the mesalamine 
enema group, respectively.
The SPD476-202 study was a phase II, multi-center, 
double-blinded, randomized dose-ranging induction study 
in mild-moderate UC (D’Haens et al 2006). The 38 patients 
were randomized to once-daily dosing of MMX mesalamine 
at doses of either 1.2, 2.4, or 4.8 g for 8 weeks. The primary 
endpoint for the study was remission at 8 weeks, deﬁ  ned as 
a UC-DAI score 1 with a score of 0 for rectal bleeding 
and stool frequency, and at least a 1-point reduction from 
baseline in sigmoidoscopy score. The secondary endpoints 
of the trial were: 1) change in UC-DAI score, 2) change in 
sigmoidoscopic appearance and histology after 8 weeks, 
and 3) change in symptoms from baseline to 2, 4, and 8 
weeks. A total of 6 patients achieved complete remission: 
4 (30.8%) in the 2.4 g/day dose group and 2 (18.2%) in the 
4.8 g/day dose group, and 0 (0%) in the 1.2 g/day dose group. 
The difference in remission rates between groups was not 
statistically signiﬁ  cant. In terms of secondary endpoints, 
patients receiving 4.8 g/day exhibited the greatest reduction 
in average UC-DAI score along with histological improve-
ments after 8 weeks. In general, MMX was well-tolerated 
among the three groups. Although the population size was 
limited (36), the data suggested that MMX mesalamine given 
at 2.4 g/day or 4.8 g/day is an effective once-daily treatment 
for mild-to-moderate UC.
Two large phase III studies (SPD476-301; SPD476-302) 
have now been completed and published, showing MMX 
mesalamine to be efﬁ  cacious for the induction of remission, 
sigmoidoscopic improvement and improvement of symptoms 
in patients with mild-to-moderate UC following 8 weeks’ 
once- or twice-daily dosing of 2.4 g/day or once-daily dosing 
of 4.8 g/day MMX mesalamine.
SPD476-301 was a randomized, double-blind, placebo-
controlled multi-center trial in 280 patients with mild-
moderate UC (Lichtenstein et al 2007). Patients were 
randomly assigned to receive either MMX mesalamine 
2.4 g/day (1.2 g tablets twice daily) or 4.8 g/day (once daily), 
or placebo for 8 weeks. The primary endpoint of the study 
was clinical and endoscopic remission at week 8, deﬁ  ned as 
1) a modiﬁ  ed UC-DAI score of 1 with 2) rectal bleeding 
and stool frequency scores of 0, and 3) at least a one-point 
reduction in the more stringent sigmoidoscopy score from 
baseline. Clinical and endoscopic remission rates at week 
8 were higher in both the 2.4 g twice daily MMX (34.1%, 
p < 0.001) and the 4.8 g once daily MMX (29.2%; p = 0.009) 
than in placebo (12.9%). Clinical improvement rates were 
55.7% and 59.6%, vs 25.9%, respectively (p < 0.001 for either 
MMX vs placebo). Sigmoidoscopic improvement rates were 
61.4% and 69.7% vs 35.5%, respectively (p < 0.01 for 4.8 g 
once daily vs placebo).
SPD476-302 was a randomized, double-blind, double-
dummy, placebo-controlled multi-center trial in 343 patients 
with mild-moderate UC (Kamm et al 2007). Patients were 
randomized to receive either MMX mesalamine 2.4 g/day 
(once daily), MMX mesalamine 4.8 g/day (once daily), pH-
release mesalamine (Asacol®) 2.4 g/day (800 mg 3 times 
daily), or placebo for 8 weeks. The primary endpoint and 
clinical and endoscopic remission at 8 weeks, as previously 
described in the SPD476-301 study, were higher in patients 
receiving either MMX 2.4 g/day (40.5%, p = 0.01 vs pla-
cebo) or MMX 4.8 g/day (41.2%, p = 0.007), but not the 
pH-release mesalamine (32.6%, p = ns), than for placebo 
(22.1%) (p = 0.033). Clinical remission rates were higher 
in the 2.4 g MMX (41.7%, p = 0.006 vs placebo) and the 
4.8 g MMX group (41.2%, p = 0.007), but not the pH-release 
mesalamine group (33.7%, p = 0.089), than in placebo 
(22.1%). Endoscopic remission rates were higher in the 2.4 
g MMX (69.0%, p = 0.003 vs placebo), the 4.8 g MMX 
(77.6%, p < 0.001), and the pH-release mesalamine (61.6%, 
p = 0.047) than for placebo (46.5%). Clinical improvement 
rates were also higher in the 2.4 g MMX (60.7%, p = 0.006 Therapeutics and Clinical Risk Management 2007:3(5) 925
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vs placebo), the 4.8 g MMX (64.7%, p < 0.001), and the 
pH-release mesalamine (55.8%, p = 0.033) than for placebo 
(39.5%).
Potential for use in clinical practice
The MMX formulation of mesalamine was FDA-approved 
for use in mild to moderate ulcerative colitis in early 2007, 
and will be sold under the brand name Lialda™ in the US and 
Mezavant™ in Europe (Shire Pharmaceuticals Inc., Wayne, 
PA, USA). Dosing will be once or twice daily, at 2.4–4.8 g 
(2–4 pills). Being the ﬁ  rst once-a-day dosed mesalamine, 
as well as one that provides over 4 g of drug with one-half 
to one-third fewer pills than the current moisture-release or 
pH-dependent release products available in the US, there has 
been much speculation as to the impact that this new formula-
tion may have upon physician prescribing habits, and patient 
demand. The results from the clinical trials reviewed above 
show that MMX dosed once daily is superior to placebo. The 
study also included a comparison of a pH-release mesalamine 
with placebo, but not MMX with pH-release mesalamine, so 
it is not possible to determine if one agent is more effective 
than the other (Kamm et al 2007).
Previous studies have suggested that the azo-bond release 
mechanism may be more effective than the pH-dependent 
release in some UC patients, based in part on the presumed 
failure of the initial pH-dependent coating to dissolve in 
individuals who do not attain such a high pH in their colon, 
which may be the problem especially in patients with active 
colitis (Fallingborg et al 1989, 1993; Green et al 1998). As 
the MMX compound also employs a similar pH-sensitive 
coating for its initial release, it too could theoretically be 
subject to this same failure.
The answers to these perplexing questions may come 
in the setting of formalized controlled comparison trials in 
the years to come. Meanwhile, the true test will occur in 
the physician’s ofﬁ  ce, with the temptation to use only 2–4 
mesalamine pills with once-daily dosing, and in the patients 
themselves, as this new formulation is used outside the con-
ﬁ  nes of controlled clinical trials. Whether physicians will 
immediately use this new agent, use it solely for patients 
newly prescribed with mesalamine or for those failing 
therapy with one of the other mesalamine agents, or switch 
patients currently responding to their current therapy will 
depend upon a few issues. One is the agent’s performance 
in the “real world”; another is patient preference, which 
may be swayed by commercial product marketing. A less 
glamorous, but perhaps more realistic view, is that the 
decision may be made by cost-conscious pharmacy beneﬁ  ts 
managers at the major health insurers and state and federal 
prescription programs, who may look solely at drug cost 
and ignore the potential cost savings of improved patient 
compliance and decreased patient relapse rates. Given the 
safety of mesalamine products, it is not unreasonable to 
afford the patient the opportunity to simplify their medica-
tion regimen, freeing themselves from repeated medication 
dosing and the constant reminder that they have a disease. 
The move to once-daily dosing with fewer pills will hope-
fully be reﬂ  ected in other novel agents and reformulations 
in the future.
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